Caris Life Sciences, Inc. (CAI)
$30.26+2.47%Close
BUYRECOVERY · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $8.6B
- Beta
- 0.68
- P/E (TTM)
- 81.35
- Short % float
- 122.99%
- Days to cover
- 2.5
- SI change
- +4.2%
- 1W
- +11.66%
- 1M
- +6.18%
- vs SPY 1W
- +11.80%
- vs SPY 1M
- +3.67%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 38
- VALUE
- 7
- GROWTH
- 52
- GARP
- 32
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC11.3%
REV YoY-
ROE18.8%
EPS YoY-
ROA8.6%
GROSS70
OP15
NET11
[VALUATION]
P/E TTM81.35
P/E FWD98.46
SECTOR PE20.48
INDUSTRY PE13.99
P/B14.46
P/FCF-
EV/EBITDA48.14
EV/EBIT-
PEG3.59
FCF YIELD-
RISK
INT COV-
D/E76.45
ALTMAN Z-
CURR RATIO5.53
ND/EBITDA-
BETA0.68
Company news
FAQ
- What is LOPJLB’s current signal on CAI?
- LOPJLB’s latest quantitative signal on Caris Life Sciences, Inc. (CAI) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is CAI in?
- Caris Life Sciences, Inc. (CAI) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Caris Life Sciences, Inc. (CAI) do?
- Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. …